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Abstract
Several mechanisms have been suggested to explain positive cardiovascular effects observed 
in studies with sodium-glucose co-transporter 2 (SGLT2) inhibitors. The reduction in glucose 
reabsorption in proximal tubuli induced by SGLT2 inhibitors increases urinary glucose and 
sodium excretion resulting in increased osmotic diuresis and consequently in decreased 
plasma volume, followed by reduced preload. In addition, the hemodynamic effects of SGLT2
inhibition were observed in both hyper and euglycemic patients. Due to the complex and 
multidirectional effects induced by SGLT2 inhibitors, this originally antidiabetic group of 
drugs has been successfully used to treat patients with heart failure as well as for subjects with
chronic kidney disease. Moreover, their therapeutic potential seems to be even broader than 
the indications studied to date.
Key words: sodium-glucose co-transporters (SGLTs), dapagliflozin, empagliflozin, heart 
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Sodium-glucose co-transporters
Sodium-glucose co-transporters (SGLTs) are a family of transmembrane proteins 
characterized by a shared transportation mechanism, in which extracellular sodium binding 
triggers a gate to open and trap glucose from outside the cell. Subsequently, the transporter 
flips releasing glucose and sodium into the cytoplasm. At the end of the process the protein 
returns to its initial conformation. SGLT1 and SGLT2 are the two most known SGLTs [1]. 
The SGLT2 is mainly expressed in the kidneys on the epithelial cells in the proximal 
convoluted tubule. In spite of low affinity for glucose, the SGLT2-mediated renal reabsorption
demonstrates a very high capacity [2]. The reabsorption of glucose can be characterized as 
sodium-dependent with ratios of 1:1 and 2:1 for SGLT2 and SGLT1, respectively [1]. With 
only a fraction of tubular glucose reabsorption being SGLT1-mediated, the majority of the 
process, approximately 90%, is handled by SGLT2. The kidney capacity of reabsorbing of 
filtered glucose represents an extremely efficient mechanism of energy conservation. Except 
for kidney, the SGLT2 expression was demonstrated in the brain, liver, thyroid, muscles, and 
heart, while the SGLT1 expression was found in the intestine, trachea, kidney, heart, brain, 
testis, and prostate [1].
Sodium-glucose co-transporters inhibition
The first description of phlorizin’s ability to block renal glucose reabsorption in 
humans was published in 1933 [3]. Phlorizin is a glucoside of phloretin (a bicyclic flavonoid),
which can mainly be found in apples, specifically in unripe fruits and root bark, as well as in 
smaller quantities in strawberries. Phlorizin, a competitive nonspecific SGLT inhibitor, 
competes for binding with D-glucose. It reduces both postprandial and fasting glycemia as 
shown in experimental animal model studies [4]. Due to these properties, orally active 
selective inhibitors of SGLT2 have been applied as antidiabetic agents. The glucose 
reabsorption limited by SGLT2 inhibitors (SGLT2i) is characterized by the rapid onset of 
glycosuria (1–2 h), the dose-dependent offset of action in the range of 24–48 h and the 
glycemia-dependent entity of glycosuria. Inhibition of SGLT2 lowers the renal glucose 
threshold into the euglycemic range. In humans, glucose reabsorption inhibition can 
maximally reach between 30% and 50% [5]. Glycosuria induced by SGLT2i in diabetic 
patients results in further metabolic changes. The decrease in fasting and postprandial plasma 
glucose concentrations is caused by a partial drainage of glucose from the extracellular space. 
Plasma insulin concentration and the secretion rate declines while plasma glucagon rises 
following the glycemia changes. A decreased insulin-to-glucagon ratio alters hepatic glucose 
metabolism, inducing endogenous fasting gluconeogenesis and attenuating its postprandial 
suppression [1]. Lower insulin levels reduce the lipolysis inhibition and cause an excess of 
free fatty acids to reach the tissues via the bloodstream. The extra free fatty acids delivery, 
together with the insulin-to-glucagon ratio reduction translates into ketogenesis [5, 6]. 
Normally, the excess of free fatty acids would lead to insulin resistance by competing with 
glucose utilization. However, on treatment with SGLT2i it is paradoxically associated with 
improved insulin sensitivity [5, 7, 8]. A schematic presentation of SGLT2 inhibitors’ 
mechanism of action is shown in the Central illustration.
Clinical effects of sodium-glucose co-transporters inhibition
The loss of glucose on SGLT inhibitors channels into a substantial, between 250 
kcal/day and 450 kcal/day, whole-body deficit of energy. However, based on this negative 
calorie balance, the weight loss observed in clinical trials was far less than expected, which 
might be explained by an increased caloric intake [9]. Countering this increase, through e.g., 
dietary counseling or pharmacological appetite quenching, could potentially strengthen the 
weight loss induced by SGLT2i [6, 9]. Complex metabolic changes induced by SGLT2i, 
including delayed clearance of low-density lipoprotein cholesterol (LDL-C) from the 
circulation along with increased plasma lipoprotein lipase activity, lead to increase of LDL-C 
and decrease of triglycerides plasma levels [8].
Additional properties of SGLT2i include a dose-dependent reduction of serum uric 
acid levels [10] as well as a reduction of urinary albumin excretion in type 2 diabetes patients 
with prevalent micro- or macroalbuminuria [11].
Several mechanisms have been suggested to explain positive cardiovascular effects 
observed in studies with SGLT2i [1, 6, 12–14]. Heart failure (HF) is a condition characterized 
by excessive accumulation of fluid in the vascular compartment as well as in the interstitial 
space. Still, many patients suffering from HF experience arterial underfilling due to a low 
cardiac output, which sometimes can be intensified by conventional treatment with diuretics. 
The reduction in glucose reabsorption in proximal tubuli induced by SGLT2i increases urinary
glucose and sodium excretion resulting in increased osmotic diuresis and consequently in 
decreased plasma volume, followed by a reduced preload [6, 15]. 
Concomitant lowering of arterial stiffness and blood pressure leads to the afterload 
reduction [6, 15]. Sympathetic activation as well as decreased arterial filling, organ perfusion 
and blood pressure constitute some of the potential negative effects of excessively reducing 
blood volume [16]. However, heart rate has not been found to increase on treatment with 
SGLT2i despite the consistent fall in arterial blood pressure in patients with type 2 diabetes, 
indicating that autonomic balance shifts toward the parasympathetic branch [1]. According to 
experimental studies, a more significant reduction of interstitial fluid volume than that of 
blood volume can be observed with SGLT2i. Hence, they could serve as better congestion 
control agents without diminishing arterial filling and tissue perfusion in contrast to 
conventional diuretic treatment [16]. The beneficial effect of SGLT2i on left ventricular (LV) 
systolic (an increase of LV ejection fraction) and diastolic (a decrease of LV filling pressure) 
function was shown in patients with HF. Moreover, a significant decrease in LV mass index, 
left atrial volume index was observed. These findings were associated with a significant 
decrease in plasma B-type natriuretic peptide concentration only in patients with a baseline 
value  100 pg/mL [17].
The hemodynamic effects of SGLT2 inhibition were observed in both hyper and 
euglycemic patients [1, 5]. Regardless of these favorable changes a decrease of hemoglobin 
A1c (HbA1c) concentration, body weight, and blood pressure, as well as an increase in 
hematocrit, hemoglobin and albumin concentration, were noted [1, 5, 12, 18–20].
It has been proposed that the SGLT2 inhibition driven effects can be explained by the 
restoration of both the anabolic and catabolic states cycling and the housekeeping processes of
the cells, which are facilitated by caloric offloading through glucosuria. This fasting-like 
effect, not seen with other antihyperglycemic drugs, triggers nutrient deprivation pathways, 
including stimulation of gluconeogenesis and ketogenesis to promote cellular homeostasis 
[21–23]. The gluconeogenesis and ketogenesis are regulated by endogenous nutrient 
deprivation sensors silent information regulator T1, proliferator-activated receptor gamma 
coactivator 1-alpha and fibroblast growth factor 21, which are known to exert cardioprotective
effects in experimental models [23]. The aforementioned benefit occurs to be mediated by 
alleviating oxidative stress and promoting autophagy. This degradative pathway plays a 
crucial role in lysosome-dependent disposing of dysfunctional cellular components that 
constitute a significant cause of cell damage [22–24]. 
On the other hand, clinical trials have not shown a reduction in HF events related to 
metformin stimulation of the adenosine monophosphate–activated protein kinase, a known 
sensor for nutrient deprivation that does not induce ketogenesis. Therefore, the main focus of 
the positive cardiovascular and renal effects of SGLT2 inhibition is the boost in ketone bodies 
production as a more potent fuel source for mitochondria compared to free fatty acids [1, 5, 
12, 13, 23, 25]. The rapid-onset renal and cardiovascular benefits demonstrated in the trials’ 
outcome remain consistent with this very elegant metabolic theory [13, 18, 19, 26].
It has also been postulated that SGLT2i directly inhibit Na+/H+ exchanger (NHE) 1, 
leading to reduced sodium and calcium cytoplasmic levels and to increase in mitochondrial 
calcium levels, thus restoring mitochondrial function and stimulating energy production [27, 
28]. 
Solini et al. [29] demonstrated the influence of dapagliflozin on the expression of 
miRNAs related to HF pathophysiology: upregulation of miR30e-5p and downregulation of 
miR199a-3p. Moreover, SGLT2 inhibition preserves renal vasodilating capacity. The 
aforementioned effects operate independently of the diuretic and blood pressure-lowering 
properties of dapagliflozin [30]. They also showed a significant dapagliflozin-induced rise in 
magnesium concentrations, which are known to be inversely associated with risk for coronary
heart disease and HF deaths. Therefore, this might contribute to the cardiovascular protection 
exerted by SGLT2i [29, 31]. 
Administration of SGLT2i is associated with the acute decrease in creatinine clearance
related to resetting macula densa tubuloglomerular feedback. Inhibition of proximal sodium 
absorption delivers an excess of sodium to the macula densa, which acts as a trigger releasing 
vasoconstrictive molecules. This mechanism results in vasoconstriction of the glomerular 
afferent arterioles reduces glomerular filtration rate and protects against the harmful impact of
blood pressure increases and fluctuations on the glomerular capillaries located downstream 
[32]. Nevertheless, the renoprotective effects that SGLT2i exert cannot be easily explained 
only by their actions to lower blood glucose, blood pressure, or glomerular filtration 
pressures.
In the cardiovascular outcome trials increase in hematocrit was observed, but the 
mechanism of this phenomenon was not clearly explained [18, 19]. In the EMPA-HEART 
study, empagliflozin use was associated with an increase in erythropoietin level. Several 
mechanisms at the kidney level may be responsible for this effect [33]. The rise in hematocrit 
suggests that SGLT2i influence hypoxia-inducible factors (HIFs; specifically, HIF-1α and 
HIF-2α). This property could be the underlying reason for their ability to prevent nephropathy
from progressing [34]. Defective nutrient deprivation signaling, oxidative and endoplasmic 
reticulum stress as well as renal hypoxia are all features of type 2 diabetes. These conditions 
tend to cause a shift in HIF-1α/HIF-2α activities ratio through simultaneous HIF-1α activation
and HIF-2α suppression. The resulting balance change stimulates profibrotic and 
proinflammatory pathways in both tubular and glomerular cells [34]. Several small studies 
with SGLT2i confirmed a slight reduction in serum inflammatory markers: high sensitivity C-
reactive protein, tumor necrosis factor-alpha, interleukin-6, and interferon-gamma, which was 
summarized by Bonnet and Sheen [30]. Moreover, SGLT2 inhibition with dapagliflozin was 
shown to slow down the progression of diabetes-associated renal tubulointerstitial fibrosis by 
improving hyperglycemia-induced activation of the signal transducer and activator of 
transcription-1/transforming growth factor-beta 1 pathway [35]. Thus, reduction of 
inflammation can be considered as another mechanism explaining the beneficial effect of 
SGLT2i at the kidney and myocardium levels.
The summary of mechanisms of SGLT2i in various clinical settings is presented in 
Table 1.
Sodium-glucose co-transporters inhibitors
Several SGLT2i have been developed, including canagliflozin, dapagliflozin, 
empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, remogliflozin, sergliflozin, 
sotagliflozin, and tofogliflozin; however, only a few of them have been tested in large-scale, 
long-term, randomized clinical trials. Only dapagliflozin and empagliflozin were evaluated in 
patients with HF regardless of a diabetes diagnosis [36–38]. Both these agents have shown 
high efficacy in reducing the primary outcome defined as a composite of worsening HF or 
cardiovascular death. Cardiovascular mortality and all-cause mortality were significantly 
decreased regardless of a diabetes diagnosis only with dapagliflozin [36], while in patients 
with type 2 diabetes, only with empagliflozin [12]. Treatment with empagliflozin and 
dapagliflozin was safe and well tolerated, resulting in excellent adherence to medication — a 
key factor in the long-term treatment of patients with chronic diseases [39, 50].
Based on the results of clinical trials, McMurray and Packer [51] proposed a new 
algorithm for the sequencing of foundational treatments in HF patients with reduced ejection 
fraction. The 3-step algorithm should be applied in a patient in whom clinical euvolemia has 
been achieved with diuretics. The treatment should be started with simultaneous initiation of 
treatment with a beta-blocker and an SGLT2i (step 1); the addition of sacubitril/valsartan (step
2); and the subsequent addition of an MRA (step 3). The proposed approach is expected to 
maximize the likelihood that highly effective therapies will be implemented in a manner that 
rapidly prevents deaths and hospitalizations and enhances the tolerability of concurrently or 
subsequently administered treatments [51].
Conclusions
Due to the complex and multidirectional mechanism of action of SGLT2i, this 
originally antidiabetic group of drugs has been successfully used to treat patients with HF and 
subjects with chronic kidney disease. Moreover, their therapeutic potential seems to be even 
wider than the indications studied so far.
Conflict of interest: Jacek Kubica, Aldona Kubica, Ryszard Gellert, Maciej Lesiak: personal 
fees from AstraZeneca; Andrzej Budaj, Jarosław Drożdż: personal fees and non-financial 
support from AstraZeneca; Tomasz Stompór: personal fees from AstraZeneca and 
Mundipharma, conduction of clinical trials sponsored by AstraZeneca; Piotr Jankowski: 
personal fees and travel grants from Boehringer-Ingelheim. All the remaining authors declare 
no conflict of interest regarding publication of this manuscript. 
References
1. Ferrannini E. Sodium-Glucose co-transporters and their inhibition: clinical physiology.
Cell Metab. 2017; 26(1): 27–38, doi: 10.1016/j.cmet.2017.04.011, indexed in Pubmed:
28506519.
2. Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: 
basic physiology and consequences. Diab Vasc Dis Res. 2015; 12(2): 78–89, doi: 
10.1177/1479164114561992, indexed in Pubmed: 25616707.
3. Chasis H, Jolliffe N, Smith HW. The action of phlorizin on the excretion of glucose, 
xylose, sucrose, creatinine and urea by man. J Clin Invest. 1933; 12(6): 1083–1090, 
doi: 10.1172/JCI100559, indexed in Pubmed: 16694183.
4. Wright EM, Loo DDF, Hirayama BA. Biology of human sodium glucose transporters. 
Physiol Rev. 2011; 91(2): 733–794, doi: 10.1152/physrev.00055.2009, indexed in 
Pubmed: 21527736.
5. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose 
cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014; 124(2): 499–
508, doi: 10.1172/JCI72227, indexed in Pubmed: 24463454.
6. Lytvyn Y, Bjornstad P, Udell JA, et al. Sodium glucose cotransporter-2 inhibition in 
heart failure: potential mechanisms, clinical applications, and summary of clinical 
trials. Circulation. 2017; 136(17): 1643–1658, doi: 
10.1161/CIRCULATIONAHA.117.030012, indexed in Pubmed: 29061576.
7. Merovci A, Abdul-Ghani M, Mari A, et al. Effect of dapagliflozin with and without 
acipimox on insulin sensitivity and insulin secretion in T2DM males. J Clin 
Endocrinol Metab. 2016; 101(3): 1249–1256, doi: 10.1210/jc.2015-2597, indexed in 
Pubmed: 26765576.
8. Basu D, Huggins LA, Scerbo D, et al. Mechanism of increased LDL (low-density 
lipoprotein) and decreased triglycerides with SGLT2 (sodium-glucose cotransporter 2)
inhibition. Arterioscler Thromb Vasc Biol. 2018; 38(9): 2207–2216, doi: 
10.1161/ATVBAHA.118.311339, indexed in Pubmed: 30354257.
9. Ferrannini G, Hach T, Crowe S, et al. Energy balance after sodium-glucose 
cotransporter 2 inhibition. Diabetes Care. 2015; 38(9): 1730–1735, doi: 10.2337/dc15-
0355, indexed in Pubmed: 26180105.
10. DeFronzo RA, Cooke CR, Andres R, et al. The effect of insulin on renal handling of 
sodium, potassium, calcium, and phosphate in man. J Clin Invest. 1975; 55(4): 845–
855, doi: 10.1172/JCI107996, indexed in Pubmed: 1120786.
11. Cherney D, Lund SS, Perkins BA, et al. The effect of sodium glucose cotransporter 2 
inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients 
with type 2 diabetes. Diabetologia. 2016; 59(9): 1860–1870, doi: 10.1007/s00125-016-
4008-2, indexed in Pubmed: 27316632.
12. Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce 
cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG 
OUTCOME trial. Diabetes Care. 2018; 41(2): 356–363, doi: 10.2337/dc17-1096, 
indexed in Pubmed: 29203583.
13. Esterline RL, Vaag A, Oscarsson J, et al. Mechanisms in endocrinology: SGLT2 
inhibitors: clinical benefits by restoration of normal diurnal metabolism? Eur J 
Endocrinol. 2018; 178(4): R113–R125, doi: 10.1530/EJE-17-0832, indexed in 
Pubmed: 29371333.
14. Jardine MJ, Mahaffey KW, Neal B, et al. CREDENCE study investigators. The 
Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical
Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am 
J Nephrol. 2017 [Epub ahead of print]; 46(6): 462–472, doi: 10.1159/000484633, 
indexed in Pubmed: 29253846.
15. Dekkers CCJ, Sjöström CD, Greasley PJ, et al. Effects of the sodium-glucose co-
transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 
2 diabetes. Diabetes Obes Metab. 2019; 21(12): 2667–2673, doi: 10.1111/dom.13855, 
indexed in Pubmed: 31407856.
16. Hallow KM, Helmlinger G, Greasley PJ, et al. Why do SGLT2 inhibitors reduce heart 
failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes 
Metab. 2018; 20(3): 479–487, doi: 10.1111/dom.13126, indexed in Pubmed: 
29024278.
17. Soga F, Tanaka H, Tatsumi K, et al. Impact of dapagliflozin on left ventricular 
diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. 
Cardiovasc Diabetol. 2018; 17(1): 132, doi: 10.1186/s12933-018-0775-z, indexed in 
Pubmed: 30296931.
18. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. 
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J 
Med. 2015; 373(22): 2117–2128, doi: 10.1056/NEJMoa1504720, indexed in Pubmed: 
26378978.
19. Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program Collaborative Group. 
Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 
2017; 377(7): 644–657, doi: 10.1056/NEJMoa1611925, indexed in Pubmed: 
28605608.
20. Phrommintikul A, Wongcharoen W, Kumfu S, et al. Effects of dapagliflozin vs 
vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery 
disease: a randomised study. Br J Clin Pharmacol. 2019; 85(6): 1337–1347, doi: 
10.1111/bcp.13903, indexed in Pubmed: 30767253.
21. Packer M. Molecular, cellular, and clinical evidence that sodium-glucose cotransporter
2 inhibitors act as neurohormonal antagonists when used for the treatment of chronic 
heart failure. J Am Heart Assoc. 2020; 9(16): e016270, doi: 
10.1161/JAHA.120.016270, indexed in Pubmed: 32791029.
22. Luo G, Jian Z, Zhu Y, et al. Sirt1 promotes autophagy and inhibits apoptosis to protect 
cardiomyocytes from hypoxic stress. Int J Mol Med. 2019; 43(5): 2033–2043, doi: 
10.3892/ijmm.2019.4125, indexed in Pubmed: 30864731.
23. Packer M. Cardioprotective effects of sirtuin-1 and its downstream effectors: potential 
role in mediating the heart failure benefits of SGLT2 (sodium-glucose cotransporter 2)
inhibitors. Circ Heart Fail. 2020; 13(9): e007197, doi: 
10.1161/CIRCHEARTFAILURE.120.007197, indexed in Pubmed: 32894987.
24. Esterline RL, Vaag A, Oscarsson J, et al. Mechanisms in endocrinology: SGLT2 
inhibitors: clinical benefits by restoration of normal diurnal metabolism? Eur J 
Endocrinol. 2018; 178(4): R113–R125, doi: 10.1530/EJE-17-0832, indexed in 
Pubmed: 29371333.
25. Neubauer S. The failing heart--an engine out of fuel. N Engl J Med. 2007; 356(11): 
1140–1151, doi: 10.1056/NEJMra063052, indexed in Pubmed: 17360992.
26. Rådholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 
diabetes mellitus. Results From the CANVAS Program. Circulation. 2018; 138(5): 
458–468, doi: 10.1161/circulationaha.118.034222, indexed in Pubmed: 29526832.
27. Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose 
cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020; 
75(4): 422–434, doi: 10.1016/j.jacc.2019.11.031, indexed in Pubmed: 32000955.
28. Baartscheer A, Schumacher CA, Wüst RCI, et al. Empagliflozin decreases myocardial 
cytoplasmic Na through inhibition of the cardiac Na/H exchanger in rats and rabbits. 
Diabetologia. 2017; 60(3): 568–573, doi: 10.1007/s00125-016-4134-x, indexed in 
Pubmed: 27752710.
29. Solini A, Seghieri M, Giannini L, et al. The effects of dapagliflozin on systemic and 
renal vascular function display an epigenetic signature. J Clin Endocrinol Metab. 
2019; 104(10): 4253–4263, doi: 10.1210/jc.2019-00706, indexed in Pubmed: 
31162549.
30. Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade 
inflammation: The potential contribution to diabetes complications and cardiovascular 
disease. Diabetes Metab. 2018; 44(6): 457–464, doi: 10.1016/j.diabet.2018.09.005, 
indexed in Pubmed: 30266577.
31. Kieboom BCT, Niemeijer MN, Leening MJG, et al. Serum magnesium and the risk of 
death from coronary heart disease and sudden cardiac death. J Am Heart Assoc. 2016; 
5(1), doi: 10.1161/JAHA.115.002707, indexed in Pubmed: 26802105.
32. Carlström M, Wilcox CS, Arendshorst WJ. Renal autoregulation in health and disease.
Physiol Rev. 2015; 95(2): 405–511, doi: 10.1152/physrev.00042.2012, indexed in 
Pubmed: 25834230.
33. Mazer CD, Hare GMT, Connelly PW, et al. Effect of empagliflozin on erythropoietin 
levels, iron stores, and red blood cell morphology in patients with type 2 diabetes 
mellitus and coronary artery disease. Circulation. 2020; 141(8): 704–707, doi: 
10.1161/CIRCULATIONAHA.119.044235, indexed in Pubmed: 31707794.
34. Packer M. Mechanisms leading to differential hypoxia-inducible factor signaling in 
the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics. Am J 
Kidney Dis. 2021; 77(2): 280–286, doi: 10.1053/j.ajkd.2020.04.016, indexed in 
Pubmed: 32711072.
35. Huang F, Zhao Y, Wang Q, et al. Dapagliflozin attenuates renal tubulointerstitial 
fibrosis associated with type 1 diabetes by regulating stat1/tgfβ1 signaling. Front 
Endocrinol. 2019; 10, doi: 10.3389/fendo.2019.00441.
36. McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF Trial Committees and 
Investigators. Dapagliflozin in patients with heart failure and reduced ejection 
fraction. N Engl J Med. 2019; 381(21): 1995–2008, doi: 10.1056/NEJMoa1911303, 
indexed in Pubmed: 31535829.
37. Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure 
with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and 
DAPA-HF trials. Lancet. 2020; 396(10254): 819–829, doi: 10.1016/S0140-
6736(20)31824-9, indexed in Pubmed: 32877652.
38. Packer M, Anker SD, Butler J, et al. EMPEROR-Reduced Trial Investigators. 
Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 
2020; 383(15): 1413–1424, doi: 10.1056/NEJMoa2022190, indexed in Pubmed: 
32865377.
39. Kubica A, Kosobucka A, Fabiszak T, et al. Assessment of adherence to medication in 
patients after myocardial infarction treated with percutaneous coronary intervention. Is
there a place for newself-reported questionnaires? Curr Med Res Opin. 2019; 35(2): 
341–349, doi: 10.1080/03007995.2018.1510385, indexed in Pubmed: 30091642.
40. Kosobucka A, Michalski P, Pietrzykowski Ł, et al. Adherence to treatment assessed 
with the adherence in chronic diseases scale in patients after myocardial infarction. 
Patient Prefer Adherence. 2018; 12: 333–340, doi: 10.2147/PPA.S150435, indexed in 
Pubmed: 29551891.
41. Kubica A, Obońska K, Fabiszak T, et al. Adherence to antiplatelet treatment with 
P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic 
review of randomized trials. Curr Med Res Opin. 2016; 32(8): 1441–1451, doi: 
10.1080/03007995.2016.1182901, indexed in Pubmed: 27112628.
42. Kubica A, Kasprzak M, Obońska K, et al. Discrepancies in assessment of adherence to
antiplatelet treatment after myocardial infarction. Pharmacology. 2015; 95(1-2): 50–
58, doi: 10.1159/000371392, indexed in Pubmed: 25592409.
43. Kubica A, Kasprzak M, Siller-Matula J, et al. Time-related changes in determinants of 
antiplatelet effect of clopidogrel in patients after myocardial infarction. Eur J 
Pharmacol. 2014; 742: 47–54, doi: 10.1016/j.ejphar.2014.08.009, indexed in Pubmed: 
25199965.
44. Pietrzykowski Ł, Kasprzak M, Michalski P, et al. Therapy discontinuation after 
myocardial infarction. J Clin Med. 2020; 9(12), doi: 10.3390/jcm9124109, indexed in 
Pubmed: 33352811.
45. Kubica A, Gruchała M, Jaguszewski M, et al. Adherence to treatment — a pivotal 
issue in long-term treatment of patients with cardiovascular diseases. An expert 
standpoint. Med Res J. 2018; 2(4): 123–127, doi: 10.5603/mrj.2017.0016.
46. Pietrzykowski Ł, Michalski P, Kosobucka A, et al. Medication adherence and its 
determinants in patients after myocardial infarction. Sci Rep. 2020; 10(1): 12028, doi: 
10.1038/s41598-020-68915-1, indexed in Pubmed: 32694522.
47. Kubica A, Adamski P, Bączkowska A, et al. The rationale for Multilevel Educational 
and Motivational Intervention in Patients after Myocardial Infarction (MEDMOTION)
project is to support multicentre randomized clinical trial Evaluating Safety and 
Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute 
Coronary Syndrome (ELECTRA – SIRIO 2). Med Res J. 2020; 5(4): 244–249, doi: 
10.5603/mrj.a2020.0043.
48. Kubica A. Self-reported questionnaires for a comprehensive assessment of patients 
after acute coronary syndrome. Med Res J. 2019; 4(2): 106–109, doi: 
10.5603/mrj.a2019.0021.
49. Kosiborod MN, Jhund PS, Docherty KF, et al. Effects of dapagliflozin on symptoms, 
function, and quality of life in patients with heart failure and reduced ejection fraction:
results from the DAPA-HF trial. Circulation. 2020; 141(2): 90–99, doi: 
10.1161/CIRCULATIONAHA.119.044138, indexed in Pubmed: 31736335.
50. Butler J, Anker SD, Filippatos G, et al. EMPEROR-Reduced Trial Committees and 
Investigators. Empagliflozin and health-related quality of life outcomes in patients 
with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. Eur 
Heart J. 2021; 42(13): 1203–1212, doi: 10.1093/eurheartj/ehaa1007, indexed in 
Pubmed: 33420498.
51. McMurray JJV, Packer M. How should we sequence the treatments for heart failure 
and a reduced ejection fraction?: A redefinition of evidence-based medicine. 
Circulation. 2021; 143(9): 875–877, doi: 10.1161/CIRCULATIONAHA.120.052926, 
indexed in Pubmed: 33378214.
Central illustration. Mechanisms of action of sodium-glucose co-transporter 2 (SGLT2) 
inhibitors.
Table 1. Multidirectional mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors 
activity in various clinical indications.






























decreased plasma BP, 
decreased inflammation, 
preserved renal 
vasodilating capacity, 
reduced glomerular 
hypertension, improved 
renal function, attenuated
diabetes-induced 
tubulointerstitial fibrosis
